<div id="readability-page-1">08:12 AM EST, 12/29/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Monday that it has signed an exclusive, expanded access distribution agreement with Irish pharmaceutical services provider Uniphar.The agreement will enable reimbursed named patient supply of Miplyffa, Zevra's treatment for Niemann-Pick disease type C, in certain territories outside of Europe, the company said.Miplyffa, or arimoclomol, is approved in the US and under review by the European Medicines Agency, the company said.Shares of Zevra were up more than 1% in recent premarket activity Monday. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

ZVRA

Zevra Therapeutics 已與 Uniphar 簽署了 Miplyffa 的獨家分銷協議，該藥物用於治療 C 型尼曼 - 匹克病，允許在歐洲以外的特定地區進行報銷供應。Miplyffa 在美國已獲得批准，並正在歐洲審核中。Zevra 的股票在盤前交易中上漲超過 1%

Zevra Therapeutics 與 Uniphar 簽署了擴展的 Miplyffa 分銷協議